FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Peptidebibliothek

KPV

Lys-Pro-Val / KPV Tripeptide

Recovery & Repair

KPV is a naturally occurring anti-inflammatory tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically representing residues 11-13 of the full hormone sequence. Despite lacking the melanocortin receptor binding core of alpha-MSH, KPV retains potent anti-inflammatory activity through direct NF-kB inhibition and has shown particular promise in inflammatory bowel disease and mucosal inflammation research. It represents a rare example of a minimal bioactive peptide fragment that maintains therapeutic activity without the parent molecule's hormonal effects.

Wirkmechanismus

C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte stimulating hormone). Potent anti-inflammatory that inhibits NF-kB translocation to the nucleus, reducing TNF-alpha, IL-6, and IL-1 beta production. Crosses the blood-brain barrier.

Forschungsprotokolle

Nur für Forschungszwecke. Keine medizinische Beratung.

Research protocols use 200-500mcg daily via subcutaneous injection or oral capsule. For gut inflammation, oral or rectal administration studied at 100-400mcg. Cycles of 4-8 weeks.

Forschungsnotizen

Clinical Research Status

KPV has not entered formal clinical trials as a standalone therapeutic but is under active preclinical investigation for inflammatory bowel disease, colitis, and dermatological conditions. Research groups at Tulane University and the University of Colorado have published extensively on its anti-inflammatory mechanisms in colonic tissue. The peptide is being explored in nanoparticle delivery systems for targeted oral delivery to inflamed intestinal mucosa. Its status remains investigational with no regulatory approvals in any jurisdiction.

Key Published Findings

A 2003 study in the Journal of Biological Chemistry demonstrated KPV enters cells and translocates to the nucleus where it directly inhibits NF-kB activation and subsequent pro-inflammatory cytokine transcription (IL-1beta, IL-6, TNF-alpha). Research published in Inflammatory Bowel Diseases showed KPV significantly reduced colonic inflammation in DSS-induced colitis models, with efficacy via both systemic injection and oral administration. Antimicrobial studies demonstrated activity against Staphylococcus aureus and Candida albicans through mechanisms independent of its anti-inflammatory pathway. A 2020 nanoparticle study showed orally-delivered KPV in hyaluronic acid-functionalized nanoparticles specifically accumulated in inflamed colonic tissue.

Safety Profile

KPV has demonstrated an excellent safety profile in all available preclinical studies with no observed toxicity at doses far exceeding therapeutic concentrations. Unlike full-length alpha-MSH, KPV has minimal melanotropic activity and does not cause skin pigmentation changes, sexual arousal, or other melanocortin-mediated effects. The tripeptide is rapidly metabolized by standard aminopeptidases, reducing risk of systemic accumulation. No adverse effects have been reported in community use, though formal human safety studies with defined endpoints have not been published.

Drug Interactions & Contraindications

No formal drug interaction studies exist, though KPV's NF-kB inhibition could theoretically potentiate other anti-inflammatory or immunosuppressive agents (TNF-alpha inhibitors, corticosteroids). Patients on biologic immunosuppressants for IBD (infliximab, adalimumab) should exercise caution with concurrent KPV due to potentially additive immunosuppression. Its antimicrobial properties suggest it should not interfere with antibiotic therapy and may provide synergistic benefit. No absolute contraindications have been identified in published literature.

Comparison to Related Compounds

Unlike its parent molecule alpha-MSH, KPV does not bind melanocortin receptors and produces no tanning, appetite suppression, or sexual side effects, isolating only the anti-inflammatory activity. Compared to BPC-157 (another gut-protective peptide), KPV works through a distinct mechanism (NF-kB inhibition vs. nitric oxide pathway modulation) and is more specifically anti-inflammatory rather than broadly tissue-protective. Relative to mesalamine (5-ASA) used in IBD, KPV acts upstream at the NF-kB level rather than downstream at the prostaglandin level. Its minimal size (3 amino acids) makes it exceptionally stable and inexpensive to synthesize compared to larger therapeutic peptides.

Community Observations

Users most commonly employ KPV for gut inflammation, often administered orally in capsule form (200-500 mcg) or subcutaneously (200-400 mcg) for systemic anti-inflammatory effects. Reports suggest noticeable improvement in IBS and IBD symptoms within 1-2 weeks of consistent use, particularly regarding abdominal pain and stool consistency. It is frequently combined with BPC-157 in gut-healing protocols, with users reporting synergistic benefits from the complementary mechanisms. Some practitioners recommend it for post-infectious gut inflammation and as part of mold/biotoxin illness recovery protocols.

Halbwertszeit

~30 minutes

Rekonstitution

Bacteriostatic water (BAC)

Lagerung

Lyophilisiert

Refrigerate 2-8C up to 12 months.

Rekonstituierter

Refrigerate 2-8C. Use within 14 days.

Rechtsstatus USA

Research chemical (not FDA-approved)

Auch bekannt als

Lys-Pro-ValKPV Tripeptide

Häufig gestellte Fragen

Was ist KPV?

KPV is a naturally occurring anti-inflammatory tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically representing residues 11-13 of the full hormone sequence. Despite lacking the melanocortin receptor binding core of alpha-MSH, KPV retains potent anti-inflammatory activity through direct NF-kB inhibition and has shown particular promise in inflammatory bowel disease and mucosal inflammation research. It represents a rare example of a minimal bioactive peptide fragment that maintains therapeutic activity without the parent molecule's hormonal effects.

Wie wirkt KPV?

C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte stimulating hormone). Potent anti-inflammatory that inhibits NF-kB translocation to the nucleus, reducing TNF-alpha, IL-6, and IL-1 beta production. Crosses the blood-brain barrier.

Wie ist der regulatorische Status von KPV in den USA?

Research chemical (not FDA-approved)

Wie lang ist die Halbwertszeit von KPV?

~30 minutes

Wie wird KPV noch genannt?

Lys-Pro-Val, KPV Tripeptide

Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.

Ganze Erklärung lesen